Registry of Lobbyists

Registration - In-house Organization

Canadian Generic Pharmaceutical Association (CGPA) / L'Association canadienne du médicament générique (ACMG) / JAMES KEON, PRESIDENT

Registration Information

In-house Organization name: Canadian Generic Pharmaceutical Association (CGPA) / L'Association canadienne du médicament générique (ACMG)
Previous in-house organization names
Responsible Officer Name: JAMES KEON, PRESIDENT 
Initial registration start date: 1998-07-22
Registration status: Active
Registration Number: 776966-548

Associated Communications

Total Number of Communication Reports: 386

Monthly communication reports in the last 6 months: 9

Version 2 of 54 (1999-01-28 to 1999-08-24)

Version 2 of 54 (1999-01-28 to 1999-08-24) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.

A. Organization Information

Organization: CANADIAN GENERIC PHARMACEUTICAL ASSOCIATION (CGPA)
409 - 4120 YONGE STREET
TORONTO, ON  M2P 2B8
Canada
Telephone number: 416-223-2333
Fax number: 416-223-2425  
Responsible officer name and position during the period of this registration: JAMES KEON, PRESIDENT  
 
Description of the organization's activities: THE CANADIAN DRUG MANUFACTURERS ASSOCIATION'S MISSION IS TO PROMOTE AN ENVIRONMENT WHICH SUPPORTS AND ENHANCES THE PROVISION OF AFFORDABLE GENERIC AND INNOVATIVE MEDICATIONS TO CANADIANS AND PATIENTS AROUND THE WORLD THROUGH RESEARCH, DEVELOPMENT AND MANUFACTURING OF PHARMACEUTICALS AND FINE CHEMICALS IN CANADA.
Organization's membership or classes of membership: THE CDMA IS COMPOSED OF 18 MEMBER COMPANIES IN THE GENERIC PHARMACEUTICAL INDUSTRY, BOTH FINE-CHEMICAL COMPANIES AND FINAL DOSAGE COMPANIES.
 
Was the organization funded in whole or in part by any domestic or foreign government institution in the last completed financial year? No
 

B. Lobbyists Employed by the Organization

Name: JAMES KEON
Position title: PRESIDENT
Public offices held: N/A. Disclosure of this information was not a requirement prior to June 20, 2005.
 
Name: PAULA REMBACH
Position title: RESEARCH ANALYST
Public offices held: N/A. Disclosure of this information was not a requirement prior to June 20, 2005.
 
Name: JULIE TAM
Position title: DIRECTOR, PROFESSIONAL & SCIENTIFIC AFFAIRS
Public offices held: N/A. Disclosure of this information was not a requirement prior to June 20, 2005.
 

C. Lobbying Activity Information

Federal departments or organizations which have been or will be communicated with during the course of the undertaking: Canadian International Development Agency (CIDA), Canadian International Trade Tribunal (CITT), Competition Tribunal (CT), Environment Canada, Federal Office of Regional Development – Quebec (FORD[Q]), Finance Canada (FIN), Foreign Affairs and International Trade Canada (DFAITC), Hazardous Materials Information Review Commission (HMIRC), Health Canada (HC), Human Resources Development Canada (HRDC), Industry Canada, Justice Canada (JC), National Research Council (NRC), Natural Sciences and Engineering Research Council (NSERC), Patented Medicine Prices Review Board (PMPRB), Privy Council Office (PCO), Revenue Canada (RC), Statistics Canada (StatCan), Treasury Board Of Canada Secretariat (TBS), Western Economic Diversification Canada (WD)
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Grass-roots communication, Informal communications, Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format
 
Subject Matter: Areas of Concern: Consumer Issues, Health, Industry, Intellectual Property, Internal Trade, International Relations, International Trade, Science and Technology, Small Business, Taxation and Finance
 
Subject Matter: Retrospective: FDA REGULATION PROPOSALS - SIZE, SHAPE AND COULOUR OF GENERIC DRUGS TRADEMARKS; DISCUSSION WITH HPB (HEALTH PROTECTION BRANCH) & INDUSTRY CANADA RE: TRADEMARKS & PHARMACEUTICALS EXPORTS; ONGOING EXCHANGE OF MATERIAL RE: PATENT RESTRICTIONS IN GENERIC PHARMACEUTICAL EXPORTS; PATENT ACT - DISCUSSION WITH GOV'T OFFICIALS RE: A QUICK REVIEW OF THE PATENT ACT; PMPRB (PATENETED MEDICINE PRICES REVIEW BOARD) - ONGOING REVIEW OF REPORTS NOTICE OF COMPLIANCE REGULATIONS - BRIEFS TO GOV'T
Subject Matter: Prospective: SIZE, SHAPE & COLOUR TRADEMARKS - SECTOR COMPETITIVENESS STUDIES WITH INDUSTRY CANADA REGARDING PHARMACEUTICAL INDUSTRY - ONGOING FOREIGN AFFAIRS & INTERNATIONAL TRADE - PROJECTS PROMOTING EXPORTS - INTERPRETATION & APPLICATION OF TRADE AGREEMENTS WITH THE GENERIC RX INDUSTRY - CONTINUATION OF NOC REGULATIONS, PATENT ACT, ANTI-COMPETIVE BEHAVIOUR.




Date Modified: